Product
Vaccine Group B: DNA-HIV-PT123 and CN54gp140+MPLA-L
1 clinical trial
1 indication
Indication
HIV InfectionsClinical trial
A Phase IIb Three-arm, Two-stage HIV Prophylactic Vaccine Trial With a Second Randomisation to Compare TAF/FTC to TDF/FTC as Pre-exposure ProphylaxisStatus: , Estimated PCD: 2024-12-31